Fetuin-A in Metabolic syndrome: A systematic review and meta-analysis

Abstract

Objective Fetuin-A has been associated with the progression of metabolic syndrome, but previous studies found inconsistent results on the relationship between metabolic syndrome and the concentration of fetuin-A. The aim of this study was to perform a meta-analysis to summarize previous findings on this relationship. Method This study was registered with the International Prospective Register of Systematic Reviews PROSPERO (CRD42019129566). Studies examining the relationship between metabolic syndrome and the concentration of circulating fetuin-A were identified using a systematic search in the electronic databases of Embase, PubMed, Web of Science, and Cochrane Library before March 2019. A random effects model was used to summarize the effect size of the association in terms of the standardized mean difference (SMD). Results Fourteen eligible studies compared fetuin-A concentrations between 4,551 metabolic syndrome patients and 8,805 controls. The circulating fetuin-A concentration was significantly higher in the metabolic syndrome patients than in the controls (SMD = 0.65, 95% confidence interval (CI): 0.48 to 0.83, Z = 7.18, p<0.001). Besides, circulating fetuin-A was a risk factor for metabolic syndrome (odds ratio 1.23, 95% CI: 1.08 to 1.40). Conclusion These findings suggest that fetuin-A may be an important indicator for metabolic syndrome, in which case this may lead to new perspectives in early diagnosis, identification of novel biomarkers, and providing novel targets for pharmacological interventions.

Chemokines in Prediabetes and Type 2 Diabetes: A Meta-Analysis

“…Noteworthy, different chemokine assessment methods were used for different studies. Therefore, to be conservative, the random-effects model was used to determine the standardized mean difference (SMD) and 95% confidence interval (CI) for continuous data (19). Using the restricted maximum-likelihood estimator, the SMD was calculated using the Cohen's d method to synthesize the effect size across studies (20,21).…”

Periodontitis, Cardiovascular Disease and Fetuin A: A Triad

“…It belongs to the cystatin superfamily and is produced majorly by hepatic and adipose tissues. Fetuin A has been recognized as a multifunctional molecule related to its role in metabolic processes, insulin resistance, regulation of adipogenesis and mineralization throughout the body [41]. FA is down-regulated by inflammatory mediators and is a negative acute phase protein [42].…”

Hepatokines and metabolism: Deciphering communication from the liver

“…Predominantly synthesized and secreted from the liver, fetuin-A is a multi-faceted protein that is an endogenous inhibitor of the insulin receptor tyrosine kinase in the liver, adipose tissue, and skeletal muscle [ 12 , [109] , [110] , [111] , [112] , [113] , [114] ] ( Figure 3 ). Patients with insulin resistance, obesity, and NAFLD have high circulating fetuin-A levels, making it a potential marker of disease prediction and diagnosis [ 12 , [115] , [116] , [117] , [118] ] ( Table 1 ). Purified rat fetuin-A dose-dependently inhibits insulin receptor tyrosine kinase activity, altering insulin signaling and ultimately resulting in insulin resistance [ 109 ] ( Figure 3 ).…”

“…Furthermore, fetuin-A is a negative regulator of the adipokine adiponectin and organokines work in concert to regulate insulin resistance ( Figure 3 ) [ 121 , 124 , 125 ]. Conversely, adiponectin has been shown to inhibit fetuin-A expression through the AMPK pathway, and it was recently suggested that hypoadiponectinemia in patients with metabolic syndrome may result in increased circulating fetuin-A [ 118 ]. In patients with type 2 diabetes, 12 weeks of calorie restriction significantly decreased circulating fetuin-A concentrations, resulting in improved visceral fat, plasma glucose, blood pressure, and lipid profiles [ 126 ].…”